Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Change in Account Payables (2023 - 2025)

CG Oncology (CGON) has disclosed Change in Account Payables for 3 consecutive years, with -$3.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables fell 242.52% year-over-year to -$3.5 million, compared with a TTM value of -$1.6 million through Dec 2025, down 150.2%, and an annual FY2025 reading of -$1.6 million, down 150.2% over the prior year.
  • Change in Account Payables was -$3.5 million for Q4 2025 at CG Oncology, down from $1.2 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $2.4 million in Q4 2024 and bottomed at -$3.5 million in Q4 2025.
  • Average Change in Account Payables over 3 years is $303583.3, with a median of $304000.0 recorded in 2025.
  • Peak annual rise in Change in Account Payables hit 15844.44% in 2024, while the deepest fall reached 442.86% in 2024.
  • Year by year, Change in Account Payables stood at $1.4 million in 2023, then skyrocketed by 76.63% to $2.4 million in 2024, then crashed by 242.52% to -$3.5 million in 2025.
  • Business Quant data shows Change in Account Payables for CGON at -$3.5 million in Q4 2025, $1.2 million in Q3 2025, and $394000.0 in Q2 2025.